Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
Authors:
- Sergi HernándezSHSergi Hernández
- Encarna NavasENEncarna Navas
- Ignacio Aznar-LouIAIgnacio Aznar-Lou
- Pilar CiruelaPCPilar Ciruela
- Juan José García-GarcíaJGJuan José García-García
- Fernando Moraga-LlopFMFernando Moraga-Llop
- Carmen Muñoz-AlmagroCMCarmen Muñoz-Almagro
- Gemma CodinaGCGemma Codina
- Mariona F. de SevillaMSMariona F. de Sevilla
- Sebastià González-PerisSGSebastià González-Peris
- Cristina EstevaCECristina Esteva
- Ana María PlanesAPAna María Planes
Open Access
Abstract
The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007–2009 (PCV7 period) and 2012–2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007–2015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) = 0.79; p = 0.036) and additional PCV13 serotypes (Pc = 0.75; p = 0.05) decreased, but those of other serotypes did not (Pc = 0.23 p = 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (3016.1 vs. 3963.9), mainly due to ICU stay (77.4%; 1051.4 vs. 1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.
Keywords
Funding Information
- Instituto de Salud Carlos III (PI11/02081 and PI 11/2345)
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 1342 and 2017 SGR 0742)
This publication has 34 references indexed in Scilit:
- Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance SitesPLOS Medicine, 2013
- Expansion of Serotype Coverage in the Universal Pediatric Vaccination Calendar: Short-Term Effects on Age- and Serotype-Dependent Incidence of Invasive Pneumococcal Clinical Presentations in Madrid, SpainClinical and Vaccine Immunology, 2013
- Impact of Introduction of Conjugate Vaccines in the Vaccination Schedule on the Incidence of Pediatric Invasive Pneumococcal Disease Requiring Hospitalization in Madrid 2007 to 2011The Pediatric Infectious Disease Journal, 2013
- Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based studyBMC Infectious Diseases, 2013
- Cost of hospitalizing children with invasive pneumococcal pneumoniaVaccine, 2013
- Healthcare utilization and cost of pneumococcal disease in the United StatesVaccine, 2011
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Costos médicos directos de enfermedades neumocócicas invasoras y neumonías con diagnóstico radiológico en niños chilenosRevista Panamericana de Salud Pública, 2009
- Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCRClinical Microbiology and Infection, 2008
- Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate VaccineClinical Infectious Diseases, 2008